Elicera Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Elicera Therapeutics CEO'su Jamal El-Mosleh, Jan2020 tarihinde atandı, in görev süresi 4.83 yıldır. şirketin hisselerinin 8.39% doğrudan sahiptir ve bu hisselerin değeri SEK 5.82M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 4.8 yıldır.

Anahtar bilgiler

Jamal El-Mosleh

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	4.8yrs
CEO sahipliği	8.4%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Jamal El-Mosleh (43 yo)

4.8yrs

Görev süresi

Mr. Jamal El-Mosleh, M.Sc., is Co-Founder at Elicera Therapeutics AB (publ) and has been its CEO since 2020. He was a Director of Elypta AB since 2016 until September 2020. Mr. El-Mosleh served as Chief Ex...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jamal El-Mosleh	CEO & Co-Founder	4.8yrs	Veri yok	8.39% SEK 5.8m
Magnus Essand	Chief Science Officer	4.8yrs	Veri yok	9.6% SEK 6.7m
Di Yu	Co-Founder & Head of Transitional Research	no data	Veri yok	9.76% SEK 6.8m
Ingvar Karlsson	Chief Financial Officer	3.8yrs	Veri yok	0.10% SEK 71.1k
Anna Gultekin	Head of Regulatory Affairs	1.8yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: ELIC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Magnus Essand	Chief Science Officer	10.8yrs	Veri yok	9.6% SEK 6.7m
Margareth Jorvid	Independent Director	4.8yrs	Veri yok	0.20% SEK 135.5k
Agneta Edberg	Independent Chairman	4.8yrs	Veri yok	0.34% SEK 237.6k
Christina Herder	Independent Director	4.8yrs	Veri yok	0.16% SEK 111.6k
Sharon Longhurst	Independent Director	less than a year	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ELIC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Elicera Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Elicera Therapeutics AB (publ), Annual General Meeting, May 16, 2024

Elicera Therapeutics AB (Publ) Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Elicera Therapeutics Includes the First Patient in the Phase I/II Clinical Study Carma Targeting B-Cell Lymphoma

Elicera Therapeutics AB (publ) Enrolls the Last Patient in the Clinical Phase I/II-Trial with Oncolytic Virus ELC-100

New major risk - Financial position

Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA

New major risk - Shareholder dilution

Elicera Therapeutics AB (publ), Annual General Meeting, May 16, 2024

New major risk - Financial position

Elicera Therapeutics AB (publ) to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1

Elicera Therapeutics AB (Publ) Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301

Elicera Therapeutics Receives Approval to Initiate Clinical Phase I/II-Study Carma with Car T-Cell Therapy ELC-301 in B-Cell Lymphoma

Elicera Therapeutics AB (publ) Co-Founder Receives Grant Totalling 4.8 million SEK from the Swedish Childhood Cancer Fund to Support Car T-Cell Research

Elicera Therapeutics AB (publ) Submits GMP Validation Data to the Swedish Medical Products Agency for the CARMA Study to Supplement the Conditionally Approved Clinical Trial Application

New major risk - Share price stability

Elicera Therapeutics AB (Publ) Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024

Elicera Therapeutics AB (publ) Receives Notice of Allowance for European Patent Protecting the iTANK

New major risk - Financial position

Elicera Therapeutics AB (publ) Submits Clinical Trial Application to Evaluate Its CAR T-Cell Therapy in B-Cell Lymphoma

Elicera Therapeutics AB (publ) Continues Phase I/IIa Study with Oncolytic Virus as Planned, Following Safety Review in Cohort 3

Elicera Therapeutics AB (publ) Announces Positive Clinical Effect in Cancer Trial

Elicera Therapeutics Reports Additional Signals of Clinical Activity in Patients Treated for Neuroendocrine Tumors in the Elc-100 Study At the Oncolytic Virotherapy Summit in Boston

Elicera Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

High number of new and inexperienced directors

Elicera Therapeutics AB (publ) Receives EUR 2.5 Million Funding to Fully Finance Clinical Phase I/II-Trial with its Car T-Cell Therapy, ELC-301

Elicera Therapeutics Successfully Concludes Preclinical Proof-Of-Concept Studies for Oncolytic Virus ELC-201 Confirming the Proposed Mode-Of-Action

High number of new and inexperienced directors

High number of new and inexperienced directors

Elicera Therapeutics AB (publ) Enters into Agreement with Baylor College of Medicine for Contract Manufacturing of Next Generation Oncolytic Virus, ELC-201

Elicera Therapeutics AB (publ) has completed an IPO in the amount of SEK 52 million.

Elicera Therapeutics AB (publ) has completed an IPO in the amount of SEK 52 million.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş